Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years Methods and results
Résumé
Aims The MITRA-FR trial showed that among symptomatic patients with severe secondary mitral regurgitation, percu-taneous repair did not reduce the risk of death or hospitalization for heart failure at 12 months compared with guideline-directed medical treatment alone. At 37 centres, we randomly assigned 304 symptomatic heart failure patients with severe secondary mitral regurgitation (effective regurgitant orifice area >20 mm 2 or regurgitant volume >30 mL), and left ventricular ejection fraction between 15% and 40% to undergo percutaneous valve repair plus medical treatment (intervention group, n = 152) or medical treatment alone (control group, n = 152). The primary efficacy outcome was the composite of all-cause death and unplanned hospitalization for heart failure at 12 months. At 24 months, all-cause death and unplanned hospitalization for heart failure occurred in 63.8% of patients (97/152) in the intervention group and 67.1% (102/152) in the control group [hazard ratio (HR) 1.01, 95% confidence interval (CI) 0.77-1.34]. All-cause *Corresponding author. Hôpital Cardiovasculaire Louis Pradel, Chirurgie Cardio-Vasculaire et Transplantation Cardiaque,
Domaines
Matériaux
Fichier principal
Iung_et_al-2019-European_Journal_of_Heart_Failure.pdf (1.17 Mo)
Télécharger le fichier
| Origine | Publication financée par une institution |
|---|
Loading...